Advertisement

Topics

Latest "A Study On Amprenavir In Combination With Other Anti-HIV Drugs In HIV-Positive Patients" News Stories

06:05 EDT 17th July 2018 | BioPortfolio

Here are the most relevant search results for "A Study On Amprenavir In Combination With Other Anti-HIV Drugs In HIV-Positive Patients" found in our extensive news archives from over 250 global news sources.

More Information about A Study On Amprenavir In Combination With Other Anti-HIV Drugs In HIV-Positive Patients on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about A Study On Amprenavir In Combination With Other Anti-HIV Drugs In HIV-Positive Patients for you to read. Along with our medical data and news we also list A Study On Amprenavir In Combination With Other Anti-HIV Drugs In HIV-Positive Patients Clinical Trials, which are updated daily. BioPortfolio also has a large database of A Study On Amprenavir In Combination With Other Anti-HIV Drugs In HIV-Positive Patients Companies for you to search.

Showing "Study Amprenavir Combination With Other Anti Drugs Positive" News Articles 1–25 of 30,000+

Tuesday 17th July 2018

Applied DNA Ships $1.15 Million Order in Fiscal 2018 Third Quarter to Tag Initial Cotton Harvest

Applied DNA Sciences, Inc. (Nasdaq:APDN) (“Applied DNA” or the ”Company“), today announced that it received and shipped a $1.15 million order in its fiscal 2018 third quarter ended June 30, 2018 to tag cotton in the upcoming 2018/2019 ginning season. The order for the Company’s SigNature T® platform technology will be used to tag, test and trac...


Allium Medical Solutions (ALMD) - Continuing to execute on an ambitious plan

Edison Investment Research - Pharmaceutical & healthcare - Allium Medical Solutions : Following broad FDA approval for Gardia, Allium anticipates the publication of clinical study results in a leading cardiology journal. Allium believes this will further increase Gardia’s attractiveness for both physicians and potential partners. Allium has secured approval for most of its urology stents and...

Metabocin shows promise as a potent anti-obesity treatment

A novel drug based on capsaicin caused long-term weight loss and improved metabolic health in mice eating a high-fat diet... The post


leon-nanodrugs Supports Takeda in a Feasibility Assessment of leon’s Proprietary MicroJet Reactor (MJR®) Nano-Technology

Munich, Germany, July 17, 2018 / B3C newswire / -- leon-nanodrugs GmbH (“leon”) is pleased to announce that its proprietary MicroJet Reactor (MJR®) nano-technology has been selected by Takeda Pharmaceutical Company Ltd. (Takeda) for a feasibility assessment that could potentially lead to the development of an innovative formulation of one of their current pipeline products. leo

VETQAS Launch New Anthrax Training Aids

VETQAS (part of APHA Scientific) are pleased to announce the launch of a new laboratory training aid. A small number of stained and mounted Anthrax blood smears are now available on a first come first serve basis at a cost of £65 (ex VAT and delivery) The chances are that many of you will have not encountered Anthrax very frequently, if at all. So it can be hard to train your team to identif...

Update on Progress of Broad Spectrum Antibiotic RECCE®327 Towards Clinical Trials

SYDNEY, Australia - 17 July 2018 - Recce Pharmaceuticals Ltd (ASX:RCE) (Company), the Company developing a new class of synthetic, broad spectrum antibiotics, today provided an update on its progress towards the start of human trials of its lead compound RECCE®327, for the treatment of sepsis, including a simple clinical trial design. RECCE®327 is being developed as a new class of a...

STAT Plus: That CRISPR study, in the cold, clear light of morning: Why it’s raising concerns

If even a few of the millions of cells returned to a patient after ex vivo editing had a tumor suppressor gene KO'd by indels gone wild, it could be…

Enzymatica AB: Lower sales in Q2 but 31% increase for the first half of the year

                                                                                       Interim report for Enzymatica AB (publ)                                                                                ...

Gut microbiota as gatekeeper of anti-tumour responses in the liver

Roche lauds new flu drug trial as Tamiflu suffers generics hit

Swiss drugmaker Roche's hopes of regaining ground in the influenza market have been boosted after a late-stage study showed its investigational drug baloxavir marboxil reduced symptoms in people at high risk of complications.

Excelera® Specialty Pharmacy Network Announces Access to Breast Cancer Treatment NERLYNX™ for Health System-based Specialty Pharmacies

The U.S. Food and Drug Administration approved NERLYNX (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer in July 2017 (https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm567309.htm). MINNEAPOLIS (PRWEB) July 17, 2018 Puma Biotechnology, Inc. and ExceleraRx® Corp. have entered into a definitive agreement whereby NERLYNX (neratinib) will be ...

OMEICOS Therapeutics Announces Compelling First-in-Human Data on Lead Compound OMT-28 and Prepares Phase 2 Trial in Atrial Fibrillation

-- High-resolution electrocardiography strongly supports OMT-28’s claim for low pro-arrhythmic risk -- OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases, today announced results from its first-in-human clinical...

Inflection Biosciences Announces Publication of Positive Data for Dual Mechanism Inhibitor Against Chronic Lymphocytic Leukaemia

Inflection Biosciences Ltd, a private company developing innovative therapeutics for cancer, today announced the publication of preclinical data showing the company’s dual mechanism PIM/PI3 kinase inhibitor IBL-202 has promise as a treatment for chronic lymphocytic leukaemia (CLL). This research has been published in the most recent issue of the p...

myStrength Launches One-to-One Coaching, Amplifying the Impact of its Digital Behavioral Health Resources

New Coaching capabilities help empower members to achieve life-improving change DENVER (PRWEB) July 17, 2018 myStrength, Inc., the digital behavioral health platform of choice for more than 150 of the largest U.S. healthcare payers and providers, is thrilled to announce the launch of its integrated Coaching feature. Coaching works with myStrength members, helping them get the most from the platfo...

Waldenstrom Macroglobulinemia Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 [Report Updated: 14022018] Prices from USD $1500

IntroductionDelveInsight's, Waldenstrom Macroglobulinemia Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018" report provides comprehensive insights about marketed and Phase III products for Waldenstrom Macroglobulinemia . The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 API manufacturer deta...

Phase III CAPSTONE-2 Study Showed That Baloxavir Marboxil Reduced Symptoms in People at High Risk of Complications From the Flu

– Baloxavir marboxil – an investigational oral, single-dose antiviral – is the first flu medicine with a novel proposed mechanism of action in nearly 20 years and to demonstrate significant efficacy in high-risk populations – – Influenza, or “flu,” represents a serious threat to public health – globally, annual epidemics result in ...

Glomerulonephritis: 2018 Pipeline Insights - Developmental Stage, Associated Indications, Route ...

ResearchAndMarkets.comLaura Wood, Senior Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900Related Topics: Liver and Kidney Disorders Drugs Read more...

Biliary Tumor: 2018 Pipeline Insights with Assessments for Active Clinical & ...

ResearchAndMarkets.comLaura Wood, Senior Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900Related Topics: Oncology Drugs Read more...

Inflection Biosciences Announces Publication of Positive Data for Dual Mechanism Inhibitor ...

Read more...

Patients with blood in stools ‘at risk of early death from ALL causes’, finds Tayside study – HeraldScotland

HeraldScotlandPatients with blood in stools 'at risk of early death from ALL causes', finds Tayside studyHeraldScotlandA BOWEL cancer test which checks for hidden blood in stools could be used to flag up people at risk of premature death from all causes, a new study suggests. Around half of people who screen positively for blood using the faecal occult blood test (FOBT ...'Invisible' stool blood l...

Monday 16th July 2018

Global Seed Industry Segmented by Product, Crop, and Geography Growth, Trends and Forecasts 2018 2023 [Report Updated: 08022018] Prices from USD $4250

The expanding world population, rising adoption of biotech crops across the world, an increase in the usage of biofuels and animal feed, and growing land reclamation for agricultural purposes are the major growth factors driving the seed market. On the other hand, the lower adoption rate of GM crops in various countries, coupled with their lengthy approval time, extensive research and time involve...

Global Styrene Isoprene Butadiene SIBS Market Segmented by Form, Product Type, EndUser Industry, and Geography Growth, Trends and Forecasts 2018 2023 [Report Updated: 08022018] Prices from USD $1923

Styrene isoprene butylene styrene SIBS is a biostable thermoplastic elastomer, with physical properties that overlap silicone rubber and polyurethane. SIBS polymer contains block segments of styrene monomers and rubber monomer units similar to other styrene block copolymers SBC. However, SIBS also contains unsaturated elastomers or rubber units having isoprene and butadiene. SIBS in general, is a ...

Variation in specialty drug coverage in the U.S.

The U.S. has a decentralized health care system.  This means that depending on your health plan, you may have more or less generous coverage.  But how does coverage vary across plans?  A recent paper by Chambers et al. (2018) looks specifically at coverage of specialty drugs.  Using the Tufts Medical Center’s Specialty Drug Evidence and Coverage…

Novartis And Cohen: A View Into Pharma's Policy Concerns As Trump Took Office

As then-Novartis CEO Joe Jimenez worked with former Trump lawyer Michael Cohen on drug pricing issues, the pharma industry wa...

Roche nabs trial win for investigational anti-viral flu drug

Roche said on Tuesday its investigational drug baloxavir marboxil reduced symptoms in people at high risk of complications from flu, a boost to the Swiss drugmaker's efforts to win approval for the single-dose, oral anti-viral medicine.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks